JP2023546915A5 - - Google Patents

Info

Publication number
JP2023546915A5
JP2023546915A5 JP2023524275A JP2023524275A JP2023546915A5 JP 2023546915 A5 JP2023546915 A5 JP 2023546915A5 JP 2023524275 A JP2023524275 A JP 2023524275A JP 2023524275 A JP2023524275 A JP 2023524275A JP 2023546915 A5 JP2023546915 A5 JP 2023546915A5
Authority
JP
Japan
Prior art keywords
solvate
pharmaceutically acceptable
acceptable salt
compound according
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000723 external-priority patent/WO2022084747A1/en
Publication of JP2023546915A publication Critical patent/JP2023546915A/ja
Publication of JP2023546915A5 publication Critical patent/JP2023546915A5/ja
Pending legal-status Critical Current

Links

JP2023524275A 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法 Pending JP2023546915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094791P 2020-10-21 2020-10-21
US63/094,791 2020-10-21
PCT/IB2021/000723 WO2022084747A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2023546915A JP2023546915A (ja) 2023-11-08
JP2023546915A5 true JP2023546915A5 (cg-RX-API-DMAC10.html) 2024-10-28

Family

ID=81290149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524275A Pending JP2023546915A (ja) 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法

Country Status (10)

Country Link
US (1) US20240158375A1 (cg-RX-API-DMAC10.html)
EP (1) EP4232458A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546915A (cg-RX-API-DMAC10.html)
KR (1) KR20230110514A (cg-RX-API-DMAC10.html)
CN (1) CN116670116A (cg-RX-API-DMAC10.html)
AU (1) AU2021363705A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196180A1 (cg-RX-API-DMAC10.html)
IL (1) IL302175A (cg-RX-API-DMAC10.html)
MX (1) MX2023004539A (cg-RX-API-DMAC10.html)
WO (1) WO2022084747A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US20260216173A1 (en) * 2022-12-20 2026-07-30 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
KR102440162B1 (ko) * 2015-07-08 2022-09-02 악세로비젼, 인크. 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
JP2023546453A5 (cg-RX-API-DMAC10.html)
JP2018528261A5 (cg-RX-API-DMAC10.html)
JP2008522981A5 (cg-RX-API-DMAC10.html)
JP2021513534A5 (cg-RX-API-DMAC10.html)
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
RU2409562C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
RU2010133903A (ru) Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты
CA2536182A1 (en) Macrocyclic peptides active against the hepatitis c virus
JP2011219498A5 (cg-RX-API-DMAC10.html)
JP2008509166A5 (cg-RX-API-DMAC10.html)
CA2504846A1 (en) Antiviral nucleoside derivatives
ES2578905T3 (es) Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
AR083161A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos
RU2409572C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
JP2016527277A5 (cg-RX-API-DMAC10.html)
RU2015101332A (ru) Новые реагенты для конъюгации
JP2023546452A5 (cg-RX-API-DMAC10.html)
JP2016529235A5 (cg-RX-API-DMAC10.html)
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
JP2009505960A5 (cg-RX-API-DMAC10.html)
CO5580743A2 (es) Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas
AR045962A1 (es) Derivados de disulfuro, sulfuro, sulfoxido y sulfona de mononitrato de 1,4:3,6 - dianhidrohexitol; sus usos en composiciones farmaceuticas para el tratamiento de enfermedades cardiovasculares y metodos para su preparacion.
JP2008531702A5 (cg-RX-API-DMAC10.html)
RU2006146215A (ru) Производные аминопропанола
CN1039318C (zh) 3,3′-联硫基二丙酸及其酯的制备方法